RY 104
Alternative Names: NG 101 - Neuracle Genetics; RY-104; RY014Latest Information Update: 25 Sep 2023
At a glance
- Originator Reyon Pharmaceutical
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Wet age-related macular degeneration
Most Recent Events
- 08 Sep 2023 Phase-I/II clinical trials in Wet age-related macular degeneration in Canada (Subretinal) (NCT05984927)
- 02 May 2023 Reyon Pharmaceuticals plans a phase I/IIa trial for Wet age-related macular degeneration in Canada in the third quarter of 2023 (NCT05984927)
- 02 May 2023 Reyon Pharmaceuticals plans a phase I/IIa trial for Wet age-related macular degeneration in USA